News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Novartis AG’s Onbrez Better Than Pfizer Inc.'s Drug Spiriva In COPD
November 3, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH, Nov 3 (Reuters) - Swiss drugmaker Novartis AG's (NOVN.VX) lung drug Onbrez reduced breathlessness more effectively than Pfizer's (PFE.N) Spiriva in patients with a deadly lung disease, a late-stage trial found.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Europe
Pfizer
Novartis
MORE ON THIS TOPIC
Lung cancer
AstraZeneca’s ATR Inhibitor Fails to Improve Survival in Phase III Lung Cancer Trial
December 22, 2025
·
1 min read
·
Annalee Armstrong
China
AstraZeneca Finds Another Jewel in China With up to $2B For KRAS Inhibitor
December 22, 2025
·
1 min read
·
Annalee Armstrong
Business
BioSpace
Editors’ Top 5 Biggest News Stories of the Year
December 22, 2025
·
10 min read
·
Annalee Armstrong
Infectious disease
Insmed Delivers ‘Rare Disappointment’ as Brinsupri Flops in Mid-Stage Rhinosinusitis Study
December 19, 2025
·
2 min read
·
Tristan Manalac
